Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cambridge Cognition Holdings PLC- Cambridge, neuroscience technology company - Wins contract with an unnamed ‘top 10’ pharmaceutical company. The contract worth over £1 million will see Cambridge Cognition provide digital cognitive assessments for a phase III autoimmune disease trial. Revenue from the contract is expected over the next three years.
‘Strategically, this contract sees the company operate in a high growth space with a leading pharmaceutical company that is committed to tackling diseases in this therapeutic area,’ says Matthew Stork, Chief Executive Officer of Cambridge Cognition.
Current stock price: 140.00 pence, up 15% on Monday
12-month change: up 65%
Copyright 2022 Alliance News Limited. All Rights Reserved.